Home › Funds › Carmignac Gestion › IONS
Carmignac Gestion position in IONS
IONIS PHARMACEUTICALS INC · Health Care
Carmignac Gestion reported holding 754,000 shares of IONS (IONIS PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$33.7M, representing 0.54% of its reported portfolio and ranking #39 among its reported holdings. Carmignac Gestion has disclosed IONS holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Carmignac Gestion's IONS position evolved
Carmignac Gestion first disclosed a stake in IONS in Q1 2026 at 53,000 shares (US$4.0M). The position peaked in Q3 2026 at 754,000 shares, worth US$33.7M. Across 3 filings, Carmignac Gestion increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 754,000 shares valued at US$33.7M — an increase of 433,000 shares quarter over quarter.. Notable position changes include a 506% increase in Q2 2026 (shares fell 44% over the following quarter), a 135% increase in Q3 2026 (shares fell 37% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 53.00K | $3.98M | New |
| Q2 2026 | 321.00K | $25.45M | Add |
| Q3 2026 | 754.00K | $33.67M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IONS and 13F data
IONS (IONIS PHARMACEUTICALS INC) is a Health Care company. 34 other funds we track also report a position in IONS — the largest reported positions include Two Sigma Investments (US$495.7M), TWO SIGMA ADVISERS, LP (US$241.5M), Deep Track Capital, LP (US$174.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IONS
- Two Sigma Investments 6.25M sh · $495.75M · Q2 2026
- TWO SIGMA ADVISERS, LP 3.05M sh · $241.45M · Q4 2025
- Deep Track Capital, LP 2.20M sh · $174.44M · Q2 2026
- BAKER BROS. ADVISORS LP 2.05M sh · $162.36M · Q2 2026
- TENOR CAPITAL MANAGEMENT Co., L.P. 94.68M sh · $147.77M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 60.00M sh · $93.10M · Q2 2026
- Tweedy, Browne Co LLC 1.79M sh · $80.08M · Q3 2026
- Bellevue Group AG 972.26K sh · $77.09M · Q2 2026
- GROUPAMA ASSET MANAGMENT 937.08K sh · $75.20M · Q2 2026
- SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 787.26K sh · $62.42M · Q2 2026
More on Carmignac Gestion
FAQ
How long has Carmignac Gestion held IONS?
Carmignac Gestion has disclosed IONS holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Carmignac Gestion's current position in IONS?
As of Q3 2026, Carmignac Gestion holds 754.00K shares of IONS (IONIS PHARMACEUTICALS INC), valued at $33.67M, representing 0.54% of its reported portfolio and ranking #39.
Has Carmignac Gestion been buying or selling IONS?
In the latest 13F filing (Q3 2026), Carmignac Gestion increased its position in IONS. The position peaked in Q3 2026 at 754.00K shares.
Which other funds hold IONS?
Other major institutional holders of IONS include Two Sigma Investments, TWO SIGMA ADVISERS, LP, Deep Track Capital, LP, among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.